PolarityBio

Executive Summary

PolarityBio is a private clinical-stage biotechnology company focused on regenerative biologics for chronic wound healing. Its lead candidate, SkinTE®, is an autologous heterogeneous skin multicellular therapy currently in a Phase III pivotal study for Wagner Grade 1 diabetic foot ulcers (DFUs). With no approved therapies addressing the underlying regenerative deficit in chronic wounds, SkinTE has the potential to offer a differentiated treatment option. The company is headquartered in San Diego and was founded in 2018. The chronic wound market is large and underserved, with DFUs representing a significant burden on healthcare systems. Positive Phase III data would position PolarityBio for a Biologics License Application (BLA) submission and potential commercialization. However, as a private company, it faces financing risks and operational challenges typical of clinical-stage biotechs. Success depends on trial execution, regulatory alignment, and securing sufficient capital to advance SkinTE through approval and launch.

Upcoming Catalysts (preview)

• H2 2026Phase III Top-Line Data for SkinTE in Diabetic Foot Ulcers45% success
• Q2 2026FDA End-of-Phase II or Pre-BLA Meeting65% success
• TBDStrategic Partnership or Licensing Deal30% success